Stay updated on Pembrolizumab in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Glioblastoma Clinical Trial page.

Latest updates to the Pembrolizumab in Glioblastoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedFooter Revision notice updated from v3.3.1 to v3.3.2. This is a minor UI/metadata change and does not affect any study details, eligibility criteria, or results.SummaryDifference0.1%

- Check27 days agoChange DetectedRevision: v3.3.1 updates the page version from v3.2.0. The study details page appears unchanged in content, with no new or altered clinical information visible.SummaryDifference0.1%

- Check35 days agoChange DetectedThe government funding operating status notice was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check49 days agoChange DetectedThe new screenshot shows an updated last update date (May 13, 2025) and minor formatting changes. There are no substantive changes to the study design, eligibility criteria, primary or secondary outcomes, or reported results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference2%

- Check85 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Glioblastoma Clinical Trial page.